Sino Biopharmaceutical Ltd
HKEX:1177

Watchlist Manager
Sino Biopharmaceutical Ltd Logo
Sino Biopharmaceutical Ltd
HKEX:1177
Watchlist
Price: 3.61 HKD -2.96% Market Closed
Market Cap: 67.8B HKD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Sino Biopharmaceutical Ltd stock under the Base Case scenario is 3.95 HKD. Compared to the current market price of 3.61 HKD, Sino Biopharmaceutical Ltd is Undervalued by 9%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
3.95 HKD
Undervaluation 9%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

2.2
P/S
P/S
Price to Sales
2.2
vs History
66
vs Industry
48
Median 3Y
2.1
Median 5Y
2.5
Industry
2.3
Forward
1.9
More Details
17.8
P/E
P/E
Price to Earnings
17.8
vs History
55
vs Industry
31
Median 3Y
17.2
Median 5Y
21
Industry
19.8
Forward
19.3
More Details
9.6
P/OCF
P/OCF
Price to OCF
9.6
vs History
76
vs Industry
38
Median 3Y
9.9
Median 5Y
11.9
Industry
14.8
More Details
14.7
P/FCFE
P/FCFE
Price to FCFE
14.7
vs History
55
vs Industry
20
Median 3Y
14.1
Median 5Y
15.5
Industry
22.2
More Details
2
P/B
P/B
Price to Book Value
2
vs History
69
vs Industry
41
Median 3Y
2
Median 5Y
2.4
Industry
1.9
More Details
1.7
EV/S
EV/S
Enterprise Value to Sales
1.7
vs History
60
vs Industry
57
Median 3Y
1.6
Median 5Y
2.1
Industry
2.4
Forward
1.5
More Details
2.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.1
vs History
61
vs Industry
71
Median 3Y
1.9
Median 5Y
2.5
Industry
4.7
More Details
7.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
7.2
vs History
71
vs Industry
43
Median 3Y
7.2
Median 5Y
8.9
Industry
12
Forward
5.9
More Details
7.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
7.2
vs History
71
vs Industry
43
Median 3Y
7.2
Median 5Y
10.2
Industry
14.9
Forward
6.9
More Details
7.7
EV/OCF
EV/OCF
Enterprise Value to OCF
7.7
vs History
71
vs Industry
44
Median 3Y
7.9
Median 5Y
9.8
Industry
13.3
More Details
8.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
8.7
vs History
74
vs Industry
33
Median 3Y
9.6
Median 5Y
12.3
Industry
17.2
More Details
1
EV/IC
EV/IC
Enterprise Value to IC
1
vs History
66
vs Industry
59
Median 3Y
1
Median 5Y
1.3
Industry
1.7
More Details

Multiples Across Competitors

Competitors Multiples
Sino Biopharmaceutical Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
HK
Sino Biopharmaceutical Ltd
HKEX:1177
66.2B HKD 2.2 17.8 7.2 7.2
US
Eli Lilly and Co
NYSE:LLY
694.1B USD 15.4 65.5 38.2 42.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
370.4B USD 4.2 26.3 12.3 16.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.4 18.5 12.2 13.9
CH
Roche Holding AG
SIX:ROG
202.8B CHF 3.5 17.6 9.9 11.8
CH
Novartis AG
SIX:NOVN
183.1B CHF 4.3 18.7 11.3 14.5
UK
AstraZeneca PLC
LSE:AZN
159B GBP 3.9 29.9 126 192.4
US
Merck & Co Inc
NYSE:MRK
193.6B USD 3 11.3 7.7 9.1
IE
Endo International PLC
LSE:0Y5F
162.4B USD 70 -55.5 259.5 650.8
FR
Sanofi SA
PAR:SAN
112.8B EUR 2.5 19.6 8.6 12.6
P/E Multiple
Earnings Growth PEG
HK
Sino Biopharmaceutical Ltd
HKEX:1177
Average P/E: 25.1
17.8
5%
3.6
US
Eli Lilly and Co
NYSE:LLY
65.5
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
26.3
26%
1
DK
Novo Nordisk A/S
CSE:NOVO B
18.5
19%
1
CH
Roche Holding AG
SIX:ROG
17.6
16%
1.1
CH
Novartis AG
SIX:NOVN
18.7
16%
1.2
UK
AstraZeneca PLC
LSE:AZN
29.9
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.3
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -55.5 N/A N/A
FR
Sanofi SA
PAR:SAN
19.6
28%
0.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
HK
Sino Biopharmaceutical Ltd
HKEX:1177
Average EV/EBITDA: 394.5
7.2
13%
0.6
US
Eli Lilly and Co
NYSE:LLY
38.2
31%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.3
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.2
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.9
7%
1.4
CH
Novartis AG
SIX:NOVN
11.3
5%
2.3
UK
AstraZeneca PLC
LSE:AZN
126
9%
14
US
Merck & Co Inc
NYSE:MRK
7.7
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
259.5
N/A N/A
FR
Sanofi SA
PAR:SAN
8.6
6%
1.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
HK
Sino Biopharmaceutical Ltd
HKEX:1177
Average EV/EBIT: 1 697.5
7.2
11%
0.7
US
Eli Lilly and Co
NYSE:LLY
42.2
33%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.2
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
13.9
16%
0.9
CH
Roche Holding AG
SIX:ROG
11.8
9%
1.3
CH
Novartis AG
SIX:NOVN
14.5
8%
1.8
UK
AstraZeneca PLC
LSE:AZN
192.4
21%
9.2
US
Merck & Co Inc
NYSE:MRK
9.1
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
650.8
N/A N/A
FR
Sanofi SA
PAR:SAN
12.6
14%
0.9

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 247,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.